Lithium induced hypercalcemia: an expert opinion and management algorithm
Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels...
Ausführliche Beschreibung
Autor*in: |
Zoltan Kovacs [verfasserIn] Peter Vestergaard [verfasserIn] Rasmus W. Licht [verfasserIn] Sune P. V. Straszek [verfasserIn] Anne Sofie Hansen [verfasserIn] Allan H. Young [verfasserIn] Anne Duffy [verfasserIn] Bruno Müller-Oerlinghausen [verfasserIn] Florian Seemueller [verfasserIn] Gabriele Sani [verfasserIn] Janusz Rubakowski [verfasserIn] Josef Priller [verfasserIn] Lars Vedel Kessing [verfasserIn] Leonardo Tondo [verfasserIn] Martin Alda [verfasserIn] Mirko Manchia [verfasserIn] Paul Grof [verfasserIn] Phillip Ritter [verfasserIn] Tomas Hajek [verfasserIn] Ute Lewitzka [verfasserIn] Veerle Bergink [verfasserIn] Michael Bauer [verfasserIn] René Ernst Nielsen [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: International Journal of Bipolar Disorders - SpringerOpen, 2013, 10(2022), 1, Seite 7 |
---|---|
Übergeordnetes Werk: |
volume:10 ; year:2022 ; number:1 ; pages:7 |
Links: |
---|
DOI / URN: |
10.1186/s40345-022-00283-3 |
---|
Katalog-ID: |
DOAJ020793006 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ020793006 | ||
003 | DE-627 | ||
005 | 20230502100140.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s40345-022-00283-3 |2 doi | |
035 | |a (DE-627)DOAJ020793006 | ||
035 | |a (DE-599)DOAJ0b61b469fe494211958f513da460d848 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC321-571 | |
050 | 0 | |a QP351-495 | |
100 | 0 | |a Zoltan Kovacs |e verfasserin |4 aut | |
245 | 1 | 0 | |a Lithium induced hypercalcemia: an expert opinion and management algorithm |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment. | ||
650 | 4 | |a Lithium | |
650 | 4 | |a Side-effects | |
650 | 4 | |a Bipolar disorder | |
650 | 4 | |a Affective disorder | |
653 | 0 | |a Neurosciences. Biological psychiatry. Neuropsychiatry | |
653 | 0 | |a Neurophysiology and neuropsychology | |
700 | 0 | |a Peter Vestergaard |e verfasserin |4 aut | |
700 | 0 | |a Rasmus W. Licht |e verfasserin |4 aut | |
700 | 0 | |a Sune P. V. Straszek |e verfasserin |4 aut | |
700 | 0 | |a Anne Sofie Hansen |e verfasserin |4 aut | |
700 | 0 | |a Allan H. Young |e verfasserin |4 aut | |
700 | 0 | |a Anne Duffy |e verfasserin |4 aut | |
700 | 0 | |a Bruno Müller-Oerlinghausen |e verfasserin |4 aut | |
700 | 0 | |a Florian Seemueller |e verfasserin |4 aut | |
700 | 0 | |a Gabriele Sani |e verfasserin |4 aut | |
700 | 0 | |a Janusz Rubakowski |e verfasserin |4 aut | |
700 | 0 | |a Josef Priller |e verfasserin |4 aut | |
700 | 0 | |a Lars Vedel Kessing |e verfasserin |4 aut | |
700 | 0 | |a Leonardo Tondo |e verfasserin |4 aut | |
700 | 0 | |a Martin Alda |e verfasserin |4 aut | |
700 | 0 | |a Mirko Manchia |e verfasserin |4 aut | |
700 | 0 | |a Paul Grof |e verfasserin |4 aut | |
700 | 0 | |a Phillip Ritter |e verfasserin |4 aut | |
700 | 0 | |a Tomas Hajek |e verfasserin |4 aut | |
700 | 0 | |a Ute Lewitzka |e verfasserin |4 aut | |
700 | 0 | |a Veerle Bergink |e verfasserin |4 aut | |
700 | 0 | |a Michael Bauer |e verfasserin |4 aut | |
700 | 0 | |a René Ernst Nielsen |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t International Journal of Bipolar Disorders |d SpringerOpen, 2013 |g 10(2022), 1, Seite 7 |w (DE-627)768094763 |w (DE-600)2732954-9 |x 21947511 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2022 |g number:1 |g pages:7 |
856 | 4 | 0 | |u https://doi.org/10.1186/s40345-022-00283-3 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/0b61b469fe494211958f513da460d848 |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.1186/s40345-022-00283-3 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2194-7511 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 10 |j 2022 |e 1 |h 7 |
author_variant |
z k zk p v pv r w l rwl s p v s spvs a s h ash a h y ahy a d ad b m o bmo f s fs g s gs j r jr j p jp l v k lvk l t lt m a ma m m mm p g pg p r pr t h th u l ul v b vb m b mb r e n ren |
---|---|
matchkey_str |
article:21947511:2022----::ihuidcdyecleiaeproiinnmn |
hierarchy_sort_str |
2022 |
callnumber-subject-code |
RC |
publishDate |
2022 |
allfields |
10.1186/s40345-022-00283-3 doi (DE-627)DOAJ020793006 (DE-599)DOAJ0b61b469fe494211958f513da460d848 DE-627 ger DE-627 rakwb eng RC321-571 QP351-495 Zoltan Kovacs verfasserin aut Lithium induced hypercalcemia: an expert opinion and management algorithm 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment. Lithium Side-effects Bipolar disorder Affective disorder Neurosciences. Biological psychiatry. Neuropsychiatry Neurophysiology and neuropsychology Peter Vestergaard verfasserin aut Rasmus W. Licht verfasserin aut Sune P. V. Straszek verfasserin aut Anne Sofie Hansen verfasserin aut Allan H. Young verfasserin aut Anne Duffy verfasserin aut Bruno Müller-Oerlinghausen verfasserin aut Florian Seemueller verfasserin aut Gabriele Sani verfasserin aut Janusz Rubakowski verfasserin aut Josef Priller verfasserin aut Lars Vedel Kessing verfasserin aut Leonardo Tondo verfasserin aut Martin Alda verfasserin aut Mirko Manchia verfasserin aut Paul Grof verfasserin aut Phillip Ritter verfasserin aut Tomas Hajek verfasserin aut Ute Lewitzka verfasserin aut Veerle Bergink verfasserin aut Michael Bauer verfasserin aut René Ernst Nielsen verfasserin aut In International Journal of Bipolar Disorders SpringerOpen, 2013 10(2022), 1, Seite 7 (DE-627)768094763 (DE-600)2732954-9 21947511 nnns volume:10 year:2022 number:1 pages:7 https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/article/0b61b469fe494211958f513da460d848 kostenfrei https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/toc/2194-7511 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2022 1 7 |
spelling |
10.1186/s40345-022-00283-3 doi (DE-627)DOAJ020793006 (DE-599)DOAJ0b61b469fe494211958f513da460d848 DE-627 ger DE-627 rakwb eng RC321-571 QP351-495 Zoltan Kovacs verfasserin aut Lithium induced hypercalcemia: an expert opinion and management algorithm 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment. Lithium Side-effects Bipolar disorder Affective disorder Neurosciences. Biological psychiatry. Neuropsychiatry Neurophysiology and neuropsychology Peter Vestergaard verfasserin aut Rasmus W. Licht verfasserin aut Sune P. V. Straszek verfasserin aut Anne Sofie Hansen verfasserin aut Allan H. Young verfasserin aut Anne Duffy verfasserin aut Bruno Müller-Oerlinghausen verfasserin aut Florian Seemueller verfasserin aut Gabriele Sani verfasserin aut Janusz Rubakowski verfasserin aut Josef Priller verfasserin aut Lars Vedel Kessing verfasserin aut Leonardo Tondo verfasserin aut Martin Alda verfasserin aut Mirko Manchia verfasserin aut Paul Grof verfasserin aut Phillip Ritter verfasserin aut Tomas Hajek verfasserin aut Ute Lewitzka verfasserin aut Veerle Bergink verfasserin aut Michael Bauer verfasserin aut René Ernst Nielsen verfasserin aut In International Journal of Bipolar Disorders SpringerOpen, 2013 10(2022), 1, Seite 7 (DE-627)768094763 (DE-600)2732954-9 21947511 nnns volume:10 year:2022 number:1 pages:7 https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/article/0b61b469fe494211958f513da460d848 kostenfrei https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/toc/2194-7511 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2022 1 7 |
allfields_unstemmed |
10.1186/s40345-022-00283-3 doi (DE-627)DOAJ020793006 (DE-599)DOAJ0b61b469fe494211958f513da460d848 DE-627 ger DE-627 rakwb eng RC321-571 QP351-495 Zoltan Kovacs verfasserin aut Lithium induced hypercalcemia: an expert opinion and management algorithm 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment. Lithium Side-effects Bipolar disorder Affective disorder Neurosciences. Biological psychiatry. Neuropsychiatry Neurophysiology and neuropsychology Peter Vestergaard verfasserin aut Rasmus W. Licht verfasserin aut Sune P. V. Straszek verfasserin aut Anne Sofie Hansen verfasserin aut Allan H. Young verfasserin aut Anne Duffy verfasserin aut Bruno Müller-Oerlinghausen verfasserin aut Florian Seemueller verfasserin aut Gabriele Sani verfasserin aut Janusz Rubakowski verfasserin aut Josef Priller verfasserin aut Lars Vedel Kessing verfasserin aut Leonardo Tondo verfasserin aut Martin Alda verfasserin aut Mirko Manchia verfasserin aut Paul Grof verfasserin aut Phillip Ritter verfasserin aut Tomas Hajek verfasserin aut Ute Lewitzka verfasserin aut Veerle Bergink verfasserin aut Michael Bauer verfasserin aut René Ernst Nielsen verfasserin aut In International Journal of Bipolar Disorders SpringerOpen, 2013 10(2022), 1, Seite 7 (DE-627)768094763 (DE-600)2732954-9 21947511 nnns volume:10 year:2022 number:1 pages:7 https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/article/0b61b469fe494211958f513da460d848 kostenfrei https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/toc/2194-7511 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2022 1 7 |
allfieldsGer |
10.1186/s40345-022-00283-3 doi (DE-627)DOAJ020793006 (DE-599)DOAJ0b61b469fe494211958f513da460d848 DE-627 ger DE-627 rakwb eng RC321-571 QP351-495 Zoltan Kovacs verfasserin aut Lithium induced hypercalcemia: an expert opinion and management algorithm 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment. Lithium Side-effects Bipolar disorder Affective disorder Neurosciences. Biological psychiatry. Neuropsychiatry Neurophysiology and neuropsychology Peter Vestergaard verfasserin aut Rasmus W. Licht verfasserin aut Sune P. V. Straszek verfasserin aut Anne Sofie Hansen verfasserin aut Allan H. Young verfasserin aut Anne Duffy verfasserin aut Bruno Müller-Oerlinghausen verfasserin aut Florian Seemueller verfasserin aut Gabriele Sani verfasserin aut Janusz Rubakowski verfasserin aut Josef Priller verfasserin aut Lars Vedel Kessing verfasserin aut Leonardo Tondo verfasserin aut Martin Alda verfasserin aut Mirko Manchia verfasserin aut Paul Grof verfasserin aut Phillip Ritter verfasserin aut Tomas Hajek verfasserin aut Ute Lewitzka verfasserin aut Veerle Bergink verfasserin aut Michael Bauer verfasserin aut René Ernst Nielsen verfasserin aut In International Journal of Bipolar Disorders SpringerOpen, 2013 10(2022), 1, Seite 7 (DE-627)768094763 (DE-600)2732954-9 21947511 nnns volume:10 year:2022 number:1 pages:7 https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/article/0b61b469fe494211958f513da460d848 kostenfrei https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/toc/2194-7511 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2022 1 7 |
allfieldsSound |
10.1186/s40345-022-00283-3 doi (DE-627)DOAJ020793006 (DE-599)DOAJ0b61b469fe494211958f513da460d848 DE-627 ger DE-627 rakwb eng RC321-571 QP351-495 Zoltan Kovacs verfasserin aut Lithium induced hypercalcemia: an expert opinion and management algorithm 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment. Lithium Side-effects Bipolar disorder Affective disorder Neurosciences. Biological psychiatry. Neuropsychiatry Neurophysiology and neuropsychology Peter Vestergaard verfasserin aut Rasmus W. Licht verfasserin aut Sune P. V. Straszek verfasserin aut Anne Sofie Hansen verfasserin aut Allan H. Young verfasserin aut Anne Duffy verfasserin aut Bruno Müller-Oerlinghausen verfasserin aut Florian Seemueller verfasserin aut Gabriele Sani verfasserin aut Janusz Rubakowski verfasserin aut Josef Priller verfasserin aut Lars Vedel Kessing verfasserin aut Leonardo Tondo verfasserin aut Martin Alda verfasserin aut Mirko Manchia verfasserin aut Paul Grof verfasserin aut Phillip Ritter verfasserin aut Tomas Hajek verfasserin aut Ute Lewitzka verfasserin aut Veerle Bergink verfasserin aut Michael Bauer verfasserin aut René Ernst Nielsen verfasserin aut In International Journal of Bipolar Disorders SpringerOpen, 2013 10(2022), 1, Seite 7 (DE-627)768094763 (DE-600)2732954-9 21947511 nnns volume:10 year:2022 number:1 pages:7 https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/article/0b61b469fe494211958f513da460d848 kostenfrei https://doi.org/10.1186/s40345-022-00283-3 kostenfrei https://doaj.org/toc/2194-7511 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2022 1 7 |
language |
English |
source |
In International Journal of Bipolar Disorders 10(2022), 1, Seite 7 volume:10 year:2022 number:1 pages:7 |
sourceStr |
In International Journal of Bipolar Disorders 10(2022), 1, Seite 7 volume:10 year:2022 number:1 pages:7 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Lithium Side-effects Bipolar disorder Affective disorder Neurosciences. Biological psychiatry. Neuropsychiatry Neurophysiology and neuropsychology |
isfreeaccess_bool |
true |
container_title |
International Journal of Bipolar Disorders |
authorswithroles_txt_mv |
Zoltan Kovacs @@aut@@ Peter Vestergaard @@aut@@ Rasmus W. Licht @@aut@@ Sune P. V. Straszek @@aut@@ Anne Sofie Hansen @@aut@@ Allan H. Young @@aut@@ Anne Duffy @@aut@@ Bruno Müller-Oerlinghausen @@aut@@ Florian Seemueller @@aut@@ Gabriele Sani @@aut@@ Janusz Rubakowski @@aut@@ Josef Priller @@aut@@ Lars Vedel Kessing @@aut@@ Leonardo Tondo @@aut@@ Martin Alda @@aut@@ Mirko Manchia @@aut@@ Paul Grof @@aut@@ Phillip Ritter @@aut@@ Tomas Hajek @@aut@@ Ute Lewitzka @@aut@@ Veerle Bergink @@aut@@ Michael Bauer @@aut@@ René Ernst Nielsen @@aut@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
768094763 |
id |
DOAJ020793006 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ020793006</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502100140.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s40345-022-00283-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ020793006</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0b61b469fe494211958f513da460d848</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC321-571</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP351-495</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Zoltan Kovacs</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Lithium induced hypercalcemia: an expert opinion and management algorithm</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lithium</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Side-effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bipolar disorder</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Affective disorder</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurosciences. Biological psychiatry. Neuropsychiatry</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurophysiology and neuropsychology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peter Vestergaard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rasmus W. Licht</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sune P. V. Straszek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anne Sofie Hansen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Allan H. Young</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anne Duffy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bruno Müller-Oerlinghausen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Florian Seemueller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gabriele Sani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janusz Rubakowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Josef Priller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Vedel Kessing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leonardo Tondo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Alda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mirko Manchia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Grof</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Phillip Ritter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomas Hajek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ute Lewitzka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Veerle Bergink</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Bauer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">René Ernst Nielsen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Bipolar Disorders</subfield><subfield code="d">SpringerOpen, 2013</subfield><subfield code="g">10(2022), 1, Seite 7</subfield><subfield code="w">(DE-627)768094763</subfield><subfield code="w">(DE-600)2732954-9</subfield><subfield code="x">21947511</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s40345-022-00283-3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0b61b469fe494211958f513da460d848</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s40345-022-00283-3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2194-7511</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">7</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Zoltan Kovacs |
spellingShingle |
Zoltan Kovacs misc RC321-571 misc QP351-495 misc Lithium misc Side-effects misc Bipolar disorder misc Affective disorder misc Neurosciences. Biological psychiatry. Neuropsychiatry misc Neurophysiology and neuropsychology Lithium induced hypercalcemia: an expert opinion and management algorithm |
authorStr |
Zoltan Kovacs |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)768094763 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC321-571 |
illustrated |
Not Illustrated |
issn |
21947511 |
topic_title |
RC321-571 QP351-495 Lithium induced hypercalcemia: an expert opinion and management algorithm Lithium Side-effects Bipolar disorder Affective disorder |
topic |
misc RC321-571 misc QP351-495 misc Lithium misc Side-effects misc Bipolar disorder misc Affective disorder misc Neurosciences. Biological psychiatry. Neuropsychiatry misc Neurophysiology and neuropsychology |
topic_unstemmed |
misc RC321-571 misc QP351-495 misc Lithium misc Side-effects misc Bipolar disorder misc Affective disorder misc Neurosciences. Biological psychiatry. Neuropsychiatry misc Neurophysiology and neuropsychology |
topic_browse |
misc RC321-571 misc QP351-495 misc Lithium misc Side-effects misc Bipolar disorder misc Affective disorder misc Neurosciences. Biological psychiatry. Neuropsychiatry misc Neurophysiology and neuropsychology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
International Journal of Bipolar Disorders |
hierarchy_parent_id |
768094763 |
hierarchy_top_title |
International Journal of Bipolar Disorders |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)768094763 (DE-600)2732954-9 |
title |
Lithium induced hypercalcemia: an expert opinion and management algorithm |
ctrlnum |
(DE-627)DOAJ020793006 (DE-599)DOAJ0b61b469fe494211958f513da460d848 |
title_full |
Lithium induced hypercalcemia: an expert opinion and management algorithm |
author_sort |
Zoltan Kovacs |
journal |
International Journal of Bipolar Disorders |
journalStr |
International Journal of Bipolar Disorders |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
container_start_page |
7 |
author_browse |
Zoltan Kovacs Peter Vestergaard Rasmus W. Licht Sune P. V. Straszek Anne Sofie Hansen Allan H. Young Anne Duffy Bruno Müller-Oerlinghausen Florian Seemueller Gabriele Sani Janusz Rubakowski Josef Priller Lars Vedel Kessing Leonardo Tondo Martin Alda Mirko Manchia Paul Grof Phillip Ritter Tomas Hajek Ute Lewitzka Veerle Bergink Michael Bauer René Ernst Nielsen |
container_volume |
10 |
class |
RC321-571 QP351-495 |
format_se |
Elektronische Aufsätze |
author-letter |
Zoltan Kovacs |
doi_str_mv |
10.1186/s40345-022-00283-3 |
author2-role |
verfasserin |
title_sort |
lithium induced hypercalcemia: an expert opinion and management algorithm |
callnumber |
RC321-571 |
title_auth |
Lithium induced hypercalcemia: an expert opinion and management algorithm |
abstract |
Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment. |
abstractGer |
Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment. |
abstract_unstemmed |
Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1 |
title_short |
Lithium induced hypercalcemia: an expert opinion and management algorithm |
url |
https://doi.org/10.1186/s40345-022-00283-3 https://doaj.org/article/0b61b469fe494211958f513da460d848 https://doaj.org/toc/2194-7511 |
remote_bool |
true |
author2 |
Peter Vestergaard Rasmus W. Licht Sune P. V. Straszek Anne Sofie Hansen Allan H. Young Anne Duffy Bruno Müller-Oerlinghausen Florian Seemueller Gabriele Sani Janusz Rubakowski Josef Priller Lars Vedel Kessing Leonardo Tondo Martin Alda Mirko Manchia Paul Grof Phillip Ritter Tomas Hajek Ute Lewitzka Veerle Bergink Michael Bauer René Ernst Nielsen |
author2Str |
Peter Vestergaard Rasmus W. Licht Sune P. V. Straszek Anne Sofie Hansen Allan H. Young Anne Duffy Bruno Müller-Oerlinghausen Florian Seemueller Gabriele Sani Janusz Rubakowski Josef Priller Lars Vedel Kessing Leonardo Tondo Martin Alda Mirko Manchia Paul Grof Phillip Ritter Tomas Hajek Ute Lewitzka Veerle Bergink Michael Bauer René Ernst Nielsen |
ppnlink |
768094763 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/s40345-022-00283-3 |
callnumber-a |
RC321-571 |
up_date |
2024-07-03T17:01:55.431Z |
_version_ |
1803578104015224832 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ020793006</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502100140.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s40345-022-00283-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ020793006</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0b61b469fe494211958f513da460d848</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC321-571</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP351-495</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Zoltan Kovacs</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Lithium induced hypercalcemia: an expert opinion and management algorithm</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background Lithium is the gold standard prophylactic treatment for bipolar disorder. Most clinical practice guidelines recommend regular calcium assessments as part of monitoring lithium treatment, but easy-to-implement specific management strategies in the event of abnormal calcium levels are lacking. Methods Based on a narrative review of the effects of lithium on calcium and parathyroid hormone (PTH) homeostasis and its clinical implications, experts developed a step-by-step algorithm to guide the initial management of emergent hypercalcemia during lithium treatment. Results In the event of albumin-corrected plasma calcium levels above the upper limit, PTH and calcium levels should be measured after two weeks. Measurement of PTH and calcium levels should preferably be repeated after one month in case of normal or high PTH level, and after one week in case of low PTH level, independently of calcium levels. Calcium levels above 2.8 mmol/l may require a more acute approach. If PTH and calcium levels are normalized, repeated measurements are suggested after six months. In case of persistent PTH and calcium abnormalities, referral to an endocrinologist is suggested since further examination may be needed. Conclusions Standardized consensus driven management may diminish the potential risk of clinicians avoiding the use of lithium because of uncertainties about managing side-effects and consequently hindering some patients from receiving an optimal treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lithium</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Side-effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bipolar disorder</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Affective disorder</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurosciences. Biological psychiatry. Neuropsychiatry</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neurophysiology and neuropsychology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peter Vestergaard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rasmus W. Licht</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sune P. V. Straszek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anne Sofie Hansen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Allan H. Young</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anne Duffy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bruno Müller-Oerlinghausen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Florian Seemueller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gabriele Sani</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Janusz Rubakowski</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Josef Priller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lars Vedel Kessing</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Leonardo Tondo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martin Alda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mirko Manchia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul Grof</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Phillip Ritter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tomas Hajek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ute Lewitzka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Veerle Bergink</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Bauer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">René Ernst Nielsen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Bipolar Disorders</subfield><subfield code="d">SpringerOpen, 2013</subfield><subfield code="g">10(2022), 1, Seite 7</subfield><subfield code="w">(DE-627)768094763</subfield><subfield code="w">(DE-600)2732954-9</subfield><subfield code="x">21947511</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s40345-022-00283-3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0b61b469fe494211958f513da460d848</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/s40345-022-00283-3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2194-7511</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">7</subfield></datafield></record></collection>
|
score |
7.3978424 |